Reduced Target Volume Significantly Reduces Late Toxicities in Extremity Sarcoma

Share this content:
Significant reduction of late toxicities in extremity soft tissue sarcoma treated with preoperative image-guided radiation therapy.
Significant reduction of late toxicities in extremity soft tissue sarcoma treated with preoperative image-guided radiation therapy.

According to a recent study published in the Journal of Clinical Oncology, researchers have found that there is a significant reduction of late toxicities in patients with extremity soft tissue sarcoma (STS) who were treated with preoperative image-guided radiation therapy (IGRT) to a reduced target volume.

For the multicenter, prospective phase II study, researchers sought to assess late toxicities in patients with STS treated with preoperative IGRT to a reduced target volume. Researchers enrolled 98 patients and assigned 12 to receive IGRT with chemotherapy (cohort A) and 86 to receive IGRT without chemotherapy (cohort B) followed by limb-sparing resection.

Cohort A was closed prematurely, and therefore only 79 patients from Cohort B were evaluable. Results showed that at a median follow-up of 3.6 years, five patients did not undergo surgery due to disease progression and five had local in-field treatment failures.

RELATED: Trabectedin Continuation vs. Interruption in Soft-Tissue Sarcoma

At 2 years, 10.5% of the evaluable 57 patients assessed for late toxicities experienced at least one grade ≥2 toxicity compared with 37% of patients reported in the National Cancer Institute of Canada SR2 study in which patients received preoperative radiation therapy without IGRT (P < 0.001).

The findings suggest that the target volumes used in this study are appropriate for patients with extremity STS receiving IGRT.

References

  1. Wang D, Zhang Q, Eisenberg BL, et al. Significant reduction of late toxicities in patients with extremity sarcoma treated with image-guided radiation therapy to a reduced target volume: results of Radiation Therapy Oncology Group RTOG-0630 Trial. J Clin Oncol. 2015. [Epub ahead of print]. doi: 10.1200/JCO.2014.58.5828.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters